How do you approach ovarian function suppression in premenopausal women with HR+/HER2-, node negative breast cancer and intermediate OncoType dx scores (11-25) who received chemotherapy?
Community PollStarted
What is your preferred adjuvant therapy for premenopausal patients with HR+/HER2- breast cancer with pN0 (OncoType 16-20/high clinical risk or 21-25) or pN1 (OncoType 0-25)?
72 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Emory University Winship Cancer Institute Midtown
Answered on · Updated on
The SOFT/TEXT data showed that the patients who benefited from ovarian suppression + endocrine therapy were those who were <35 years old or those who had prior chemotherapy (essentially those patients who were deemed to have high risk disease). The TAILORx study demonstrated that patients with recur...
Join for free or sign in to see the full answer